Atyr Pharma Inc (ATYR) 13F Positioning & Ownership Changes (Q2 2026)

ATYR ranks #4732 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ATYR is a disclosed holding of Cliff Asness (AQR Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

94 institutions disclose a position in ATYR, but none treat it as a major bet — even Kalehua Capital Management LLC, its most concentrated holder, allocates just 0.6% of its own portfolio to it.

XTX Topco Ltd has added to its ATYR position for two straight quarters, increasing it by $73.1K to reach $135.3K today.

Fidelity has trimmed its ATYR position for two straight quarters, cutting it by $10.0M while still holding $1.5M.

ATYR is up 3.4% today, but institutions show net selling of $9.0M this quarter — a divergence between today's price move and the underlying institutional flow.

ATYR reported a net loss of $60.8M over the trailing twelve months.

• Not yet profitable — net loss of $60.8M over the trailing twelve months
• Revenue declined 19.1% year over year
• Net income improved year over year, from -$66.6M to -$60.8M
• Operating cash flow was negative, using $62.0M in cash
• Current ratio of 5.30x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.38x equity — within a conventional range